Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
September 2022
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/ard-2022-222487.
Large multinational, multiethnic cohort, study highlights the importance of treating-to-target in SLE.
Keywords:
Trajectory of Damage Accrual in Systemic Lupus Erythematosus based on Ethnicity and Socioeconomic Factors
J Rheumatol. 2022. Epub ahead of print doi: 10.3899/jrheum.211135
Large study confirms that cumulative damage accrual is faster in African-Americans, compared to Caucasians, highlighting that ethnicity plays the major role in damage accrual, regardless of socioeconomic status.
February 2022
Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.
January 2022
2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus
Clin Rheumatol. 2021. Epub ahead of print
Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.